|
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NOT_RECRUITINGPhase 3Sponsored by Eli Lilly and Company
No longer actively recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-05-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations35 sites
View on ClinicalTrials.gov →
NCT06993792
Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Eligibility
Age: 18 Years+Healthy volunteers accepted
There are no specific eligibility criteria for the Master Protocol. * See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes * See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
Conditions4
DiabetesObesityOverweightType 2 Diabetes
Interventions1
Locations35 sites
Clinical Research Institute of Arizona (CRI) - Sun City West
623-293-1360
Find trials near these locations
Related trials
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) — Eli Lilly and Company
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee — Eli Lilly and Company
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-05-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations35 sites
View on ClinicalTrials.gov →
NCT06993792